Temperature-induced gradient self-gas-producing composition and use thereof
By using a temperature-induced gradient self-generating gas composition, the complexity and risks of existing airbag implantation weight reduction methods have been solved, achieving safe and convenient airbag inflation and efficient gas production. It is suitable for intragastric volume reduction and weight reduction as well as limb compression hemostasis.
Patent Information
- Application Number
- PCT/CN2024/094344
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2024-05-21
- Publication Date
- 2024-11-28
AI Technical Summary
Existing methods of weight loss via airbag implantation require professional medical intervention and involve uncontrollable chemical reactions and risks, making it difficult to achieve safe and convenient airbag inflation within the body.
The gas-generating composition using temperature-induced gradient is composed of components A, B, C, D, and E. It utilizes the body's internal temperature to induce gas production, avoiding chemical reactions and ensuring the safe inflation of the airbag within the body.
It enables safe and convenient inflation of the airbag inside the body, with high utilization rate of the gas-generating agent and high gas volume ratio, reducing the risk of use, and is suitable for intragastric volume reduction and weight reduction and limb compression hemostasis.
Smart Images

Figure CN2024094344_28112024_PF_FP_ABST
Abstract
Description
A temperature-induced gradient self-gas-generating composition and its application Technical Field
[0001] The present invention relates to the technical field of medical devices, and in particular to a temperature-induced gradient self-gas-generating composition and an application thereof in a self-expanding medical air bag. Background Art
[0002] Compression is a common surgical treatment, and various airbags are commonly used compression devices. Airbag compression can effectively stop bleeding from limb trauma and certain intra-abdominal bleeding. Especially for limb traumatic bleeding, the use of a pneumatic tourniquet is the preferred emergency treatment. In the treatment of obesity, placing an airbag in the stomach can occupy gastric volume, reduce food intake, and achieve the goal of weight loss. This method has been clinically applied abroad and has been proven to be a safe, simple, and effective weight loss method.
[0003] However, current balloon implantation weight loss methods require an empty balloon connected to a catheter and then inserted into the stomach. This procedure, which requires a professional doctor to perform, can be uncomfortable for the patient. Researchers have been working on improvements to this approach. Document CN200810300628.8[P] reports on a "self-inflating balloon within the digestive tract lumen." Two gas-producing reactants, hydrogen peroxide and ferrous sulfate, are placed within the balloon, isolated in separate compartments within the bundled balloon. Once mixed, these reactants generate gas. CN200420032735.4[P] also reports on a "self-inflating intragastric weight loss capsule." The gas-producing substances used in this capsule are inorganic salts and organic acids, which react in the presence of water. The inorganic salts include potassium carbonate, sodium carbonate, sodium bicarbonate, and potassium bicarbonate, while the organic acids include acetic acid, citric acid, and malic acid. While the aforementioned patent avoids external inflation and saline injection, it is also bulky and difficult to swallow. Chemical reactions within the body pose certain risks, and the gas production reaction is difficult to control within the bladder. Therefore, further improvements are needed to expand the application of this product in weight loss and surgical treatments.
[0004] Summary of the Invention
[0005] In view of the shortcomings of the existing technology, the present invention proposes a temperature-induced gradient self-gas-generating composition, and applies it to intragastric filling-type non-drug weight loss treatment or trauma emergency treatment.
[0006] To achieve the purpose of the present invention, the technical solution adopted by the present invention is:
[0007] The temperature-induced gradient self-gassing composition is composed of the following components, with each component being expressed in percentage by mass: component A 1%-20%, component B 5%-30%, component C 55%-95%, component D 0.05%-0.5%, and component E 0.05%-0.5%.
[0008] Preferably, the self-gas generating composition comprises: component A 1%-10%, component B 5%-20%, component C 70%-90%, component D 0.05%-0.5%, and component E 0.05%-0.5%.
[0009] The component A is selected from: any one or both of 1,1,1,3,3-pentafluoropropane-ethanol azeotrope and trans-1-chloro-3,3,3-trifluoropropene, wherein the mass percentage of ethanol in the 1,1,1,3,3-pentafluoropropane-ethanol azeotrope is 1%-20%.
[0010] The component B is selected from: any one or both of 1,1,1,3,3-pentafluorobutane-ethanol azeotrope and monofluorotrichloromethane, wherein the mass percentage of ethanol in the 1,1,1,3,3-pentafluorobutane-ethanol azeotrope is 1%-20%.
[0011] The component C is selected from any one or more of cis-1,1,1,4,4,4-hexafluoro-2-butene, 1,1,1,3,3-pentafluorobutane, and 1-fluoro-1,1-dichloroethane.
[0012] Component D is a flavor alerting agent, selected from any one or more of eugenol, cinnamaldehyde, eucalyptus essential oil, lavender essential oil, basil essential oil, fennel essential oil, peppermint essential oil, rosemary essential oil, and patchouli essential oil. Its function is to release the essential oil into the stomach after an accidental rupture of the airbag, and the odor of the essential oil can be released through hiccups, signaling the rupture of the airbag.
[0013] Component E is a color-generating alerting agent, and its material is selected from any one or more of Prussian blue, methylene blue, and anthocyanin. Its function is to turn urine blue when released into the stomach after the balloon accidentally ruptures, indicating balloon rupture.
[0014] The sum of the proportions of the various components is A%+B%+C%+D%+E%=100%.
[0015] The prepared gas-generating agent is placed in the airbag, excess air is expelled and the bag is sealed. It is then folded into a specific shape according to different uses and then packaged as a whole to make a temperature-induced gradient self-gas-generating airbag, which can be used for internal body or limb compression hemostasis or gastric volume and weight reduction.
[0016] When using an intragastric volume-reducing and weight-reducing airbag for obesity treatment, a corresponding volume-reducing and weight-reducing capsule can be further made. After the capsule is swallowed into the stomach, the gas-generating agent sealed in the airbag induces gradient gasification under the temperature of 37°C-40°C in the human stomach. Within a preset time, the gastric-soluble encapsulated capsule gradually disintegrates, and the airbag fills and expands to a predetermined volume, occupying the corresponding stomach volume, thereby reducing food intake and achieving weight loss.
[0017] The gas generating agent of this invention triggers gas production by gas generation in the stomach, a physical method that eliminates the need for complex initiating gas generation equipment. Component C and its dosage ensure that the balloon does not expand or vaporize within 2 to 15 seconds of storage and passage through the esophagus after swallowing. The appropriate dosages of components A and B ensure that the balloon enters the stomach and the gas generating agent fully vaporizes, expanding to a diameter of 70 to 75 mm. The maximum size of an object that can pass through the pylorus is no more than 40 mm, so a balloon of this diameter is guaranteed to prevent it from entering the intestines through the pylorus.
[0018] When used for gastric volume and weight reduction, the gas-generating agent is fully vaporized, the balloon is inflated, and the internal pressure is maintained at or slightly above the intragastric pressure, with a maximum pressure not exceeding 0.05 MPa. When used for limb compression hemostasis, the gas-generating agent is fully vaporized, the balloon is fully inflated, and combined with the strapping tape, the internal pressure is maintained at the required level to stop bleeding, with a maximum pressure not exceeding 0.1 MPa.
[0019] The principle of the present invention is physical gas production, which uses the internal body temperature, the body surface temperature, and the ambient temperature to induce the gradient gasification of the gas generating agent composition. It does not require matching inflation or chemical reaction equipment. The gas generating agent utilization rate is nearly 100%, and less gas generating agent can produce more gas. The main components of the selected composition are biologically inert compounds, and all components are harmless to the human body. The toxicological data of each component are as follows: 1,1,1,3,3-pentafluoropropane toxicological data: No toxicity via the dermal route. When rats and mice were exposed to 203,000ppm or 101,000ppm of pentafluoropropane, there was no mortality or significant signs of toxicity (Toxicological Sciences, 1999, 52(2): 289–301). Toxicological data for trans-1-chloro-3,3,3-trifluoropropene: It is non-mutagenic and non-teratogenic. Its toxicity to rodents was negative in genotoxicity tests, and its toxicity potential to mammals is very low. Male Sprague-Dawley rats and female New Zealand white rabbits were exposed to 2000, 5000, and 10,000 PPM of trans-1-chloro-3,3,3-trifluoropropene, respectively. Urine collected for 48 hours after six hours of exposure showed no detectable toxicants (Toxicology and Applied Pharmacology, 2013, 268:343–351). Toxicological data of monofluorotrichloromethane: Male and female F-344 rats were exposed to 6 hours / day, 5 days / week, with average levels of 0, 29, 62 and 121 ppm for 13 weeks, without causing any signs of poisoning (JOURNAL OF THE AMERICAN COLLEGE OF TOXICOLOGY, 1988, 7(5)663-674). Cis-1,1,1,4,4,4-hexafluoro-2-butene Toxicology Data: The 4-hour LC50 in rats is 1425 ppm. Fischer-344 rats were exposed to HFIB for 6 hours per day, 5 days per week, at average HFIB concentrations of 3, 10, 30, and 90 ppm for 13 weeks, with no animal deaths (TOXICOLOGY AND APPLIED PHARMACOLOGY, 1986, 86:327-340). Toxicological data of 1-fluoro-1,1-dichloroethane: It has very low acute toxicity. Application of 2000 mg / kg body weight to rabbit skin did not produce adverse reactions. Oral administration of 5000 mg / kg body weight did not cause death or clinical symptoms of toxicity in rats. The 4-hour LC50 in rats is approximately 62000 ppm. Repeated exposure of rats to concentrations of 2000, 8000, or 20000 ppm for 6 hours / day, 5 days / week, and up to 90 days did not produce significant adverse reactions (Food and Chemical Toxicology, 1995, 33(6): 483-490). Toxicological data of 1,1,1,3,3-pentafluorobutane: The toxicological indicators are all lower than those of 1-fluoro-1,1-dichloroethane, making it safer to use in the present invention (JOURNAL OF CELLULAR PLASTICS, 1999, 35: 328-331).
[0020] Trans-1-chloro-3,3,3-trifluoropropene has been used in the medical field. See the authorized Chinese invention patent CN201180065331, which records that "…suitable materials to be sprayed include, but are not limited to, cosmetic materials such as deodorants, fragrances, hair sprays, cleaning solvents and lubricants, and medical materials such as antiasthmatics. The term medical material is used in its broadest sense herein to include any and all materials that are effective or at least considered to be effective in treatment, diagnostic methods, analgesia and similar therapies, and thus includes, for example, drugs and biologically active substances. This includes, for example, the compositions of the present invention in aerosols for delivering drugs to the lungs or mucosa. Examples include metered dose inhalers (MDIs) for treating asthma and other chronic obstructive pulmonary diseases and for delivering drugs to accessible mucosa or intranasal."
[0021] Advantages of the present invention: The amount of gas produced by a capsule of a certain volume can be described as the gas production volume ratio: V2 / V1, where V1 is the initial volume of the capsule and V2 is the volume of the balloon after expansion. A smaller initial volume of the capsule is convenient for swallowing independently, but after entering the stomach, it is expected to be filled into a larger balloon. According to different application scenarios, the conventional operating temperature range of the gas generator of the present invention can be set to 15°C-45°C. At 38°C and 1 standard atmospheric pressure, 1.04 grams of the gas generator of the present invention can be gasified into approximately 200mL of gas, and the gas production volume ratio is much higher than that of the acid-base reaction type gas generator. Therefore, the gas generator provided by the present invention can make the packaging size of various air bags smaller, especially the gastric volume-reducing and weight-reducing air bags. The smaller volume is convenient for swallowing, and it is safer and more convenient to use. According to the literature [ANNALS OF BIOMEDICAL ENGINEERING, 2021, 49:1391–1401], existing acid-base reaction-type gas-generating weight loss airbags can produce 120mL of gas from 1.12g of an acid-base reactant and 1mL of water. (Calculations show that the total volume of the acid-base gas generator is approximately 1.53mL. The present invention requires approximately 0.63g of gas generator to produce 120mL of gas, with a volume of approximately 0.50mL, which is approximately 33% of the total volume of the acid-base reaction-type gas generator.) Furthermore, the present invention employs physical gas generation, utilizing internal body and surface temperatures, as well as ambient temperature, to induce gradient gas production from the composition, avoiding chemical reactions and reducing the risks of use.
[0022] When used for gastric volume reduction and weight loss, after the gas-generating agent is placed in the airbag, air is removed, and the capsule is folded and sealed, the total volume of all materials is approximately 2.5mL (V1). The capsule dimensions are approximately: diameter 12mm, length 25mm; the diameter of the filled airbag is 73-75mm, and the occupied volume is approximately 200mL (V2). The gas production volume ratio (V2 / V1) of the present invention can reach 80 (the gas production volume ratio is 2.4 times that of the prior art). The filling amount of the gas-generating agent can also be appropriately increased to obtain a larger filling volume and gas production volume ratio. When the gas production volume is the same, the volume of the capsule of the present invention is less than 1 / 2 of that of existing acid-base reaction products, making it easy for patients to swallow it on their own. Only 1-2 capsules need to be swallowed at a time to meet treatment needs, achieving the current common weight loss efficacy volume. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 is a schematic diagram of a comprehensive detection device for a gas generating agent according to the present invention, wherein 1-1 is a synchronous constant temperature chamber; 1-2 is a constant temperature water bath; 1-3 is water; 1-4 is a precision pressure gauge; 1-5 is a pressure test gas generating bottle; 1-6 is an air bag test port; 1-7 is a gas production test bottle (gas production measurement by water displacement method); 1-8 is a graduated cylinder; 1-9 is a material test kettle; 1-10 is a membrane material pressure resistance test port; 1-11 is a membrane material barrier property test port; 1-12 is a valve; and 1-13 is a thermometer.
[0024] FIG2 is a diagram of a swallowing and intragastric test model device, wherein 2-1 is a constant temperature water bath, 2-2 is water, 2-3 is esophagus, 2-4 is a capsule entering the esophagus, 2-5 is stomach, 2-6 is a simulated gastric content, and 2-7 is an air bag in a filled and inflated state.
[0025] FIG3 is a temperature-expansion volume curve of Example 1 of the present invention.
[0026] FIG4 is a temperature-pressure curve of Example 1 of the present invention. DETAILED DESCRIPTION
[0027] In order to better illustrate the present invention, the present invention is described in detail below with reference to the embodiments and the accompanying drawings.
[0028] Example 1
[0029] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:
[0030] 1% azeotrope of 1,1,1,3,3-pentafluoropropane (97%) and ethanol (3%) and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of the two is 1:1); 20% mixture of monochlorotrifluoromethane and azeotrope of 1,1,1,3,3-pentafluorobutane (95%) and ethanol (5%) (mass ratio of the two is 1:2); 78% mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (mass ratio of the three is 4:3:3); 0.5% eugenol; 0.5% methylene blue.
[0031] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 1-7 (water displacement method) in Figure 1 for testing. At temperatures below 30°C, the gas production was 0 mL. At 31°C-34°C, the gas production within 2 minutes was 2.1 mL. At 31°C-34°C, the gas production within 2-10 minutes was 9.7 mL. At 35°C-38°C, the gas production within 2 minutes was 158.9 mL. The maximum gas production at 38°C was 194.0 mL.
[0032] Example 2
[0033] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:
[0034] 3% azeotrope of 1,1,1,3,3-pentafluoropropane (97%)-ethanol (3%) and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of the two is 1:1); 20% azeotrope of monofluorotrichloromethane and 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%) (weight ratio of the two is 1:2); 76% mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (weight ratio of the three is 4:3:3); 0.5% lavender essential oil; 0.5% Prussian blue.
[0035] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottles 1-7 (water displacement method) in Figure 1 for testing. At temperatures below 30°C, the gas production was 0 mL. At 31°C-34°C, the gas production within 2 minutes was 6.4 mL. At 31°C-34°C, the gas production within 2-10 minutes was 14.0 mL. At 35°C-38°C, the gas production within 2 minutes was 157.3 mL. The maximum gas production at 38°C was 194.5 mL.
[0036] Example 3
[0037] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:
[0038] 7% of 1,1,1,3,3-pentafluoropropane (97%)-ethanol (3%) azeotrope and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of 1:1); 5% of monochlorotrifluoromethane and 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%) azeotrope (weight ratio of 1:1); 87% of a mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (weight ratio of 4:3:3); 0.5% eugenol; 0.5% methylene blue.
[0039] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 1-7 in Figure 1 (gas production measurement by water displacement method) for testing. The gas production below 30°C was 1.0 mL, the gas production within 2 minutes at 31-34°C was 14.9 mL, the gas production within 2-10 minutes at 31°C-34°C was 15.6 mL, the gas production within 2 minutes at 35°C-38°C was 171.4 mL, and the maximum gas production at 38°C was 195.4 mL.
[0040] Example 4
[0041] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:
[0042] 10% azeotrope of 1,1,1,3,3-pentafluoropropane (97%)-ethanol (3%) and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of the two is 1:1); 5% azeotrope of monofluorotrichloromethane and 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%) (weight ratio of the two is 1:1); 84% mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (weight ratio of the three is 4:3:3); 0.5% eugenol; 0.5% methylene blue.
[0043] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 1-7 in Figure 1 (gas production measurement by water displacement method) for testing. The gas production below 30°C was 2.1 mL, the gas production within 2 minutes at 31°C-34°C was 21.2 mL, the gas production within 2-10 minutes at 31°C-34°C was 21.7 mL, the gas production within 2 minutes at 35°C-38°C was 168.0 mL, and the maximum gas production at 38°C was 196.7 mL.
[0044] Example 5
[0045] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:
[0046] 1%, ...
[0047] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 1-7 in Figure 1 (gas production measurement by water displacement method) for testing. The gas production was 0 mL below 30°C, 2.1 mL within 2 minutes at 31°C-34°C, 4.0 mL within 2-10 minutes at 31°C-34°C, 171.6 mL within 2 minutes at 35°C-38°C, and 195.9 mL at 38°C.
[0048] Example 6
[0049] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:
[0050] 1%, 1,1,1,3,3-pentafluoropropane (97%)-ethanol (3%) azeotrope and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of the two is 1:1) 1%; 8%, 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%) azeotrope (weight ratio of the two is 1:1) 1%; 90%, a mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (weight ratio of the three is 4:3:3) 0.5% eugenol; 0.5% methylene blue.
[0051] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 1-7 in Figure 1 (gas production measurement by water displacement method) for testing. The gas production was 0 mL below 30°C, 2.1 mL within 2 minutes at 31°C-34°C, 3.1 mL within 2-10 minutes at 31°C-34°C, 174.6 mL within 2 minutes at 35°C-38°C, and 197.2 mL at 38°C.
[0052] Example 7
[0053] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:
[0054] 1% azeotrope of 1,1,1,3,3-pentafluoropropane (97%)-ethanol (3%) and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of 1:1); 5% azeotrope of monofluorotrichloromethane and 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%) (weight ratio of 1:1); 93.8% mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (weight ratio of 4:3:3); 0.1% eugenol; 0.1% methylene blue.
[0055] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 1-7 in Figure 1 (gas production measurement by water displacement method) for testing. The gas production was 0 mL below 30°C, 2.1 mL within 2 minutes at 31°C-34°C, 2.7 mL within 2-10 minutes at 31°C-34°C, 180.3 mL within 2 minutes at 35°C-38°C, and 199.1 mL at 38°C.
[0056] Example 8
[0057] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:
[0058] trans-1-chloro-3,3,3-trifluoropropene 15%; monochlorotrifluoromethane 15%; 1-fluoro-1,1-dichloroethane 69.8%; fennel essential oil 0.1%; anthocyanidin 0.1%.
[0059] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 1-7 in Figure 1 (gas production measurement by water displacement method) for testing. The gas production was 4.8 mL below 30°C, 32.0 mL within 2 minutes at 31°C-34°C, 36.4 mL within 2-10 minutes at 31°C-34°C, 172.5 mL within 2 minutes at 35°C-38°C, and 196.7 mL at 38°C.
[0060] Example 9
[0061] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:
[0062] 20% blend of 1,1,1,3,3-pentafluoropropane (95%)-ethanol (5%) azeotrope and trans-1-chloro-3,3,3-trifluoropropene (weight ratio 1:2); 25% azeotrope of 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%); 54.8% cis-1,1,1,4,4,4-hexafluoro-2-butene; 0.1% lavender essential oil; 0.1% Prussian blue.
[0063] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 1-7 in Figure 1 (gas production measurement by water displacement method) for testing. The gas production below 30°C was 7.8 mL, the gas production within 2 minutes at 31°C-34°C was 40.0 mL, the gas production within 2-10 minutes at 31°C-34°C was 62.6 mL, the gas production within 2 minutes at 35°C-38°C was 132.8 mL, and the maximum gas production at 38°C was 178.5 mL.
[0064] Example 10
[0065] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:
[0066] 5% blend of 1,1,1,3,3-pentafluoropropane (95%)-ethanol (5%) azeotrope and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of the two is 1:2); 30% azeotrope of 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%); 64% cis-1,1,1,4,4,4-hexafluoro-2-butene; 0.1% lavender essential oil; 0.1% Prussian blue.
[0067] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 1-7 in Figure 1 (gas production measurement by water displacement method) for testing. The gas production below 30°C was 0.5 mL, the gas production within 2 minutes at 31°C-34°C was 10.2 mL, the gas production within 2-10 minutes at 31°C-34°C was 55.4 mL, the gas production within 2 minutes at 35°C-38°C was 152.3 mL, and the maximum gas production at 38°C was 195.1 mL.
[0068] Example 11
[0069] The swallowing and gastric test model apparatus shown in Figure 2 was used to simulate gastric gas production. The gastric contents consisted of a mixture of water, carboxymethyl cellulose, milk, vegetable pulp, and preservatives adjusted to pH 3 with 0.1 M hydrochloric acid.
[0070] A 200mL airbag was fabricated using a 0.06mm-thick PA / EVOH / PE composite film. 1.0g of the gas generating agent from Example 1 of the present invention was placed within the airbag. After removing air, the airbag was sealed, folded, and then placed within a 12mm diameter, 25mm length gastric-soluble capsule to create a weight-loss capsule model. The capsule was then injected into the model stomach via the esophagus with 50mL of 25°C warm water. The gastric contents were set to a preset temperature of 38°C. Observation under polarized backlight transillumination revealed that the capsule disintegrated 24 minutes after entering the stomach, at which point the airbag began to gradually expand with gas production. Expansion ceased at 265 seconds, reaching its maximum diameter of 75mm, resulting in a volume of approximately 200mL.
[0071] Comparative Example 1
[0072] The gas generating agent is composed of the following components (in the absence of component A), and each component is expressed in weight percentage:
[0073] 30% azeotropic mixture of monofluorotrichloromethane and 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%) (weight ratio of the two is 1:2); 69% mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (weight ratio of the three is 4:3:3); 0.5% eugenol; 0.5% methylene blue.
[0074] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 1-7 in Figure 1 (gas production measurement by water displacement method) for testing. Under conditions below 30°C, the gas production was 0 mL, 1.3 mL within 2 minutes at 31°C-34°C, 40.1 mL within 10 minutes at 31°C-34°C, 150.4 mL within 2 minutes at 35°C-38°C, and the maximum gas production was 193.4 mL at 38°C for 10 minutes.
[0075] Comparative Example 2
[0076] The gas generating agent is composed of the following components (absent component B), each component is expressed in weight percentage:
[0077] 20% 1,1,1,3,3-pentafluoropropane (97%)-ethanol (3%) azeotrope and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of 1:1); 79.8% mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (weight ratio of 4:3:3); 0.1% lavender essential oil; 0.1% Prussian blue.
[0078] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 1-7 in Figure 1 (gas production measurement by water displacement method) for testing. The gas production below 30°C was 8.5 mL, the gas production within 2 minutes at 31°C-34°C was 42.4 mL, the gas production within 2-10 minutes at 31°C-34°C was 43.7 mL, the gas production within 2 minutes at 35°C-38°C was 166.8 mL, and the maximum gas production at 38°C was 198.5 mL.
[0079] The experimental results of the embodiment and comparative example are shown in Table 1.
[0080] Table 1
[0081] It can be seen from the test results of Examples 1, 2, 3, 5, 6, 7, and 10 that the gas generating agent does not vaporize or vaporizes in small amounts at room temperature below 30°C. During the swallowing process, the gas generating agent gradually heats up in the esophagus within 2 seconds to 15 seconds, and the overall gasification temperature is not reached. In a temperature environment of 37°C to 40°C in the human stomach (the temperature range in the stomach of some people has been actually measured by the inventor and confirmed in combination with literature data), the gas production continues to increase. In order to prevent the capsule from accidentally expanding in the esophagus, a gastric-soluble pressure-bearing packaging capsule can be used to pressure-proof the airbag. Before entering the esophagus and reaching the stomach, even if the temperature in the esophagus reaches the gasification temperature of the gas generating agent, the airbag can still be guaranteed not to expand, thereby further improving safety.
[0082] It can be seen from the test results of Examples 4, 8, and 9 that when component A accounts for a larger proportion, the gradient gas production rate is faster at room temperature below 30°C.
[0083] From the test results of Comparative Examples 1-2, it can be seen that when components A and B are missing respectively, the gas production in the range of 31°C-34°C for 2 minutes to 10 minutes is large, and the temperature gradient self-gas production effect is poor.
[0084] According to the experimental results of the examples and comparative examples, the preferred composition of the gas generating agent is: A 1%-10%, component B 5%-20%, component C 70%-90%, component D 0.05%-0.5%, and component E 0.05%-0.5%. Among them, Example 5 is preferred.
[0085] The gas generating agent of the present invention can fill the air bag to about 200 ml in 10 minutes at a temperature within the range of 35-40° C. in the human stomach, and can keep the volume substantially unchanged for 180 days.
[0086] Typically, a weight loss treatment cycle lasts for 180 days. At the end of treatment (or when needed at any time), a needle can be used to pierce the balloon under gastroscopy to extract the gas. After the gas is basically extracted, the deflated balloon can be grabbed through the gastroscope and removed. The balloon can also be made of degradable materials. After the treatment cycle is completed, the balloon degrades and collapses, leaking gas. The deflated balloon remains are discharged from the body through the intestines. The possibility of accidental damage to the balloon cannot be ruled out. In this case, the gas leaks and the balloon deflates, and the remains can be discharged from the body through the intestines. The leaked gas stays in the stomach for a short time and then quickly discharges itself through the digestive tract.
[0087] The gas generating agent composition of the present invention can also be made into a self-expanding compression medical air bag for intra-abdominal compression hemostasis, limb compression hemostasis and the like.
Claims
1. A temperature-induced gradient self-gassing composition, characterized in that: It is composed of the following components, each component is calculated by mass percentage: component A 1%-20%, component B 5%-30%, component C 55%-95%, component D 0.05%-0.5%, component E 0.05%-0.5%; The component A is selected from: any one or two of 1,1,1,3,3-pentafluoropropane-ethanol azeotrope or trans-1-chloro-3,3,3-trifluoropropene, wherein the mass percentage of ethanol in the 1,1,1,3,3-pentafluoropropane-ethanol azeotrope is 1%-20%; The component B is selected from: any one or two of 1,1,1,3,3-pentafluorobutane-ethanol azeotrope or monofluorotrichloromethane, wherein the mass percentage of ethanol in the 1,1,1,3,3-pentafluorobutane-ethanol azeotrope is 1%-20%; The component C is selected from any one or more of cis-1,1,1,4,4,4-hexafluoro-2-butene, 1,1,1,3,3-pentafluorobutane, and 1-fluoro-1,1-dichloroethane; The component D is a taste alerting agent, selected from any one or more of eugenol, cinnamaldehyde, eucalyptus essential oil, lavender essential oil, basil essential oil, fennel essential oil, peppermint essential oil, rosemary essential oil, and patchouli essential oil; The component E is a color alerting agent selected from any one or more of Prussian blue, methylene blue, and anthocyanin.
2. The temperature-induced gradient self-gassing composition according to claim 1, characterized in that: It consists of the following components, each component is calculated by weight percentage: component A 1%-10%, component B 5%-20%, component C 70%-90%, component D 0.05%-0.5%, component E 0.05%-0.5%.
3. Use of the temperature-induced gradient self-gassing composition according to claim 1 or 2, characterized in that: It can be made into self-gas-generating gastric volume and weight reduction capsules or self-expanding compression medical air bags.
Citation Information
Patent Citations
Capsule type self-gas-production stomach volume-reduction and weight-reduction airbag
CN116602807A
Temperature-induced gradient gas self-production composition and application thereof
CN116603067A
Compositions of pentafluoropropane
CN1653155A
Weight-reducing capsule with automatic fill in stomach
CN2754630Y
Intragastric device with self-deflation
WO2019112768A1
